REMARKS

The specification has been amended in order to update the cross-reference to related application information.

Claims 2, 5, 6, 9, 12-27, and 46-53, which are directed to subject matter which was elected for prosecution in prior application are canceled. Claim 7 is canceled and replaced by new claim 54.

Claim 1 is amended to exclude therefrom the subject matter elected for prosecution in the parent application and to correspond to the format of the claims allowed in the parent. Support for the amended definition of X is found in the specification at page 5, line 9, to page 6, line 18, and the amendment of the definition of Y^1 and Y^2 to include alkoxy (1-6C) finds support in the specification, for example, at page 14, line 33; page 15, lines 1, 4, and 5; page 19, lines 4, 5, 8, 9, 12-14, 25, and 26, and page 21, lines 30 and 31.

New claim 55 further limits claim 54 to the compounds in which X is C_1-C_4-alkoxy-substituted C_1-C_4-alkyl.

Claims 1, 3, 4, 8, 10, 11, 28-45, 54, and 55 are in the application as amended.

Attached hereto is a marked-up version of the changes made to the specification and claims by the instant amendment. The marked-up version is entitled "Version With Markings To Show Changes Made".

Respectfully submitted,

Dated: 12/17/01

PAUL E. DUPONT
Registration No. 27,438

Sanofi-Synthelabo Inc.
9 Great Valley Parkway
Malvern, PA 19355
Tel.: (610) 889-6338
Fax: (610) 889-8799

Version With Markings to Show Changes Made

In the specification

On page 1, immediately after the title of the invention, a cross reference to related application section was inserted.

In the Claims:

Claims 1, 3, 4, 8, and 10 have been amended as follows:

1. (Amended) A method of selectively killing hypoxic tumor cells sensitive to the compounds of the formula in a host comprising administering to said [cells] host an effective amount of a pharmaceutical composition comprising a compound of the formula



wherein X is H; hydrocarbyl (1-4C) substituted with OH, NH_2, NHR or NRR; halogen; OH; or C_1-C_4-alkoxy where each R is independently an alkyl of 1-4 carbon atoms or acyl of 1-4 carbon atoms, or wherein in the case of NRR the two R groups may be linked together to form a morpholino, pyrrolidino or piperidino ring, and wherein R may be further substituted with OH, NH_2, alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, morpholino, pyrrolidino, piperidino, alkoxy (1-4C), or halogen substituents;

n is 1; and

Y^1 and Y^2 are independently either H; nitro; halogen; alkoxy (1-6C); hydrocarbyl (1-14C) including cyclic and unsaturated hydrocarbyl, optionally substituted with 1 or 2 substituents selected from the group consisting of halogen, hydroxy, epoxy, alkoxy (1-4C), alkylthio (1-4C), primary amino (NH_2), lower alkyl (1-4C) secondary amino, dialkyl (1-4C) tertiary amino, dialkyl (1-4C) tertiary amino where the two alkyls are linked together to produce a morpholino, pyrrolidino or piperidino, acyloxy (1-4C), acylamido (1-4C) and thio analogs thereof,

acetylaminoalkyl (1-4C), carboxy, alkoxycabonyl (1-4C), carbamyl, alkylcarbamyl (1-4C), alkylsulfonyl (1-4C) or alkylphosphonyl (1-4C), wherein the hydrocarbyl can optionally be interrupted by a single ether (-0-) linkage; or wherein Y^1 and Y^2 are independently either morpholino, pyrrolidino, piperidino, NH_2, NHR', NR'R' O(CO)R', NH(CO)R', O(SO)R', or O(POR')R' in which R' is a hydrocarbyl (1-4C) which may be substituted with OH, NH_2, alkyl-(1-4C) secondary amino, dialkyl (1-4C) tertiary amino, morpholino, pyrrolidino, piperidino, alkoxy (1-4C), or halogen substitutents, or a pharmacologically acceptable salt of said compound.

3. (Amended) The method of claim [2,] 1 wherein Y^1 and Y^2 are both H.

4. (Amended) The method of claim [2,] 1 wherein Y^1 is H and Y^2 is nitro.

8. (Amended) The method of claim [7,] 54 wherein X is H.

10. (Amended) The method of claim [7,] 54 wherein Y^1 and Y^2 are both H.

Claims 2, 5-7, 9, 12-27, and 46-53 have been canceled and new claims 54 and 55 have been added.